Agios Pharmaceuticals IncNASDAQ:AGIO
- LAST PRICE53.7800
- TODAY'S CHANGE (%)-1.6200 (-2.9242%)
- Bid / Lots53.4100/ 1
- Ask / Lots54.2300/ 1
- Open / Previous Close55.6700 / 55.4000
- Day Range
- 52 Week Range
- Volume926,800
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGIO |
|---|---|---|
| 09:32 ET | 17561 | 55.67 |
| 09:33 ET | 749 | 55.215 |
| 09:35 ET | 1160 | 54.887 |
| 09:37 ET | 1800 | 53.78 |
| 09:39 ET | 1000 | 53.71 |
| 09:42 ET | 3257 | 53.445 |
| 09:44 ET | 1300 | 53.35 |
| 09:46 ET | 1917 | 53.1 |
| 09:48 ET | 995 | 53.13 |
| 09:50 ET | 1514 | 52.995 |
| 09:51 ET | 3863 | 53.32 |
| 09:53 ET | 3258 | 53.625 |
| 09:55 ET | 1400 | 53.68 |
| 09:57 ET | 600 | 53.805 |
| 10:00 ET | 579 | 53.9 |
| 10:02 ET | 3610 | 54.11 |
| 10:04 ET | 14542 | 53.8939 |
| 10:06 ET | 13151 | 54 |
| 10:08 ET | 901 | 54.045 |
| 10:09 ET | 3116 | 54.05 |
| 10:11 ET | 300 | 54 |
| 10:13 ET | 5213 | 53.77 |
| 10:15 ET | 800 | 53.42 |
| 10:18 ET | 700 | 53.32 |
| 10:20 ET | 800 | 53.27 |
| 10:22 ET | 1100 | 53.08 |
| 10:24 ET | 1819 | 52.98 |
| 10:26 ET | 1653 | 52.82 |
| 10:27 ET | 1100 | 52.97 |
| 10:29 ET | 2696 | 52.75 |
| 10:31 ET | 3700 | 53.11 |
| 10:33 ET | 1100 | 53.21 |
| 10:36 ET | 4387 | 53.49 |
| 10:38 ET | 900 | 53.505 |
| 10:40 ET | 600 | 53.59 |
| 10:42 ET | 1500 | 53.39 |
| 10:44 ET | 2500 | 53.265 |
| 10:45 ET | 500 | 53.17 |
| 10:47 ET | 1000 | 52.99 |
| 10:49 ET | 1100 | 53.1 |
| 10:51 ET | 2700 | 53.3125 |
| 10:54 ET | 2260 | 53.255 |
| 10:56 ET | 2096 | 53.16 |
| 10:58 ET | 2823 | 53.21 |
| 11:00 ET | 600 | 53.21 |
| 11:02 ET | 5036 | 53.17 |
| 11:03 ET | 709 | 53.1 |
| 11:05 ET | 3757 | 53.25 |
| 11:07 ET | 5500 | 53.29 |
| 11:09 ET | 4842 | 53.33 |
| 11:12 ET | 4943 | 53.385 |
| 11:14 ET | 5288 | 53.36 |
| 11:16 ET | 2900 | 53.67 |
| 11:18 ET | 400 | 53.905 |
| 11:20 ET | 400 | 53.93 |
| 11:21 ET | 1914 | 53.825 |
| 11:23 ET | 795 | 53.84 |
| 11:25 ET | 886 | 53.84 |
| 11:27 ET | 1200 | 53.8 |
| 11:30 ET | 1790 | 53.87 |
| 11:32 ET | 1822 | 53.855 |
| 11:34 ET | 500 | 53.72 |
| 11:36 ET | 500 | 53.64 |
| 11:38 ET | 1300 | 53.59 |
| 11:39 ET | 900 | 53.62 |
| 11:41 ET | 200 | 53.63 |
| 11:43 ET | 200 | 53.615 |
| 11:45 ET | 1308 | 53.47 |
| 11:48 ET | 1068 | 53.465 |
| 11:50 ET | 500 | 53.435 |
| 11:52 ET | 4999 | 53.62 |
| 11:54 ET | 307 | 53.615 |
| 11:56 ET | 526 | 53.64 |
| 11:59 ET | 10323 | 53.915 |
| 12:01 ET | 4781 | 53.85 |
| 12:03 ET | 787 | 53.8675 |
| 12:06 ET | 300 | 53.905 |
| 12:08 ET | 930 | 53.66 |
| 12:10 ET | 1100 | 53.62 |
| 12:12 ET | 400 | 53.615 |
| 12:14 ET | 320 | 53.52 |
| 12:15 ET | 600 | 53.56 |
| 12:17 ET | 500 | 53.555 |
| 12:19 ET | 700 | 53.605 |
| 12:21 ET | 200 | 53.56 |
| 12:24 ET | 600 | 53.535 |
| 12:26 ET | 200 | 53.56 |
| 12:28 ET | 200 | 53.56 |
| 12:30 ET | 1339 | 53.46 |
| 12:32 ET | 1300 | 53.335 |
| 12:33 ET | 300 | 53.33 |
| 12:35 ET | 400 | 53.335 |
| 12:37 ET | 1900 | 53.16 |
| 12:39 ET | 600 | 53.26 |
| 12:42 ET | 400 | 53.23 |
| 12:44 ET | 500 | 53.13 |
| 12:46 ET | 3397 | 53.12 |
| 12:48 ET | 1000 | 53.04 |
| 12:50 ET | 1200 | 52.99 |
| 12:51 ET | 2776 | 53 |
| 12:53 ET | 600 | 53.01 |
| 12:55 ET | 2308 | 53.11 |
| 12:57 ET | 1100 | 53.08 |
| 01:00 ET | 500 | 53.02 |
| 01:02 ET | 600 | 53.105 |
| 01:04 ET | 1100 | 53.14 |
| 01:06 ET | 600 | 53.145 |
| 01:08 ET | 300 | 53.12 |
| 01:09 ET | 1000 | 53.23 |
| 01:11 ET | 1229 | 53.17 |
| 01:13 ET | 3297 | 53.22 |
| 01:15 ET | 5750 | 53.44 |
| 01:18 ET | 900 | 53.515 |
| 01:20 ET | 743 | 53.47 |
| 01:22 ET | 700 | 53.55 |
| 01:24 ET | 1000 | 53.65 |
| 01:26 ET | 700 | 53.67 |
| 01:27 ET | 700 | 53.69 |
| 01:29 ET | 1300 | 53.75 |
| 01:31 ET | 500 | 53.805 |
| 01:33 ET | 1509 | 53.74 |
| 01:36 ET | 4925 | 53.86 |
| 01:38 ET | 400 | 53.885 |
| 01:40 ET | 3620 | 53.87 |
| 01:42 ET | 1050 | 53.79 |
| 01:44 ET | 2400 | 53.77 |
| 01:45 ET | 500 | 53.755 |
| 01:47 ET | 3040 | 53.84 |
| 01:49 ET | 1715 | 53.8 |
| 01:51 ET | 300 | 53.8 |
| 01:54 ET | 1211 | 53.79 |
| 01:56 ET | 520 | 53.75 |
| 01:58 ET | 1100 | 53.81 |
| 02:00 ET | 900 | 53.76 |
| 02:02 ET | 600 | 53.71 |
| 02:03 ET | 900 | 53.6 |
| 02:05 ET | 1000 | 53.6 |
| 02:07 ET | 3169 | 53.48 |
| 02:09 ET | 1806 | 53.43 |
| 02:12 ET | 5027 | 53.24 |
| 02:14 ET | 900 | 53.17 |
| 02:16 ET | 700 | 53.14 |
| 02:18 ET | 600 | 53.09 |
| 02:20 ET | 4615 | 53.005 |
| 02:21 ET | 300 | 53.005 |
| 02:23 ET | 600 | 53.01 |
| 02:25 ET | 2100 | 53.035 |
| 02:27 ET | 1404 | 53.205 |
| 02:30 ET | 5044 | 53.22 |
| 02:32 ET | 2152 | 53.23 |
| 02:34 ET | 2500 | 53.38 |
| 02:36 ET | 2600 | 53.4375 |
| 02:38 ET | 7500 | 53.51 |
| 02:39 ET | 2998 | 53.565 |
| 02:41 ET | 1826 | 53.76 |
| 02:43 ET | 2820 | 53.765 |
| 02:45 ET | 1200 | 53.715 |
| 03:15 ET | 7912 | 53.705 |
| 03:17 ET | 2100 | 53.71 |
| 03:19 ET | 1700 | 53.67 |
| 03:21 ET | 3181 | 53.665 |
| 03:24 ET | 2300 | 53.665 |
| 03:26 ET | 3600 | 53.825 |
| 03:28 ET | 3500 | 53.82 |
| 03:30 ET | 4650 | 53.785 |
| 03:32 ET | 4946 | 53.7 |
| 03:33 ET | 2946 | 53.77 |
| 03:35 ET | 5160 | 53.75 |
| 03:37 ET | 5103 | 53.85 |
| 03:39 ET | 1000 | 53.795 |
| 03:42 ET | 5835 | 53.595 |
| 03:44 ET | 2400 | 53.62 |
| 03:46 ET | 3438 | 53.575 |
| 03:48 ET | 5270 | 53.62 |
| 03:50 ET | 11383 | 53.65 |
| 03:51 ET | 6013 | 53.6 |
| 03:53 ET | 17678 | 53.805 |
| 03:55 ET | 22182 | 53.84 |
| 03:57 ET | 10722 | 53.82 |
| 04:00 ET | 157810 | 53.78 |
Nov 5, 2024
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition, from 9:05AM ET on Tuesday Nov 05, 2024 by Dow Jones
9:05AM ET on Tuesday Nov 05, 2024 by Dow Jones
Nov 1, 2024
DJ Agios Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 12:43PM ET on Friday Nov 01, 2024 by Dow Jones
12:43PM ET on Friday Nov 01, 2024 by Dow JonesDJ Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank, from 10:30AM ET on Friday Nov 01, 2024 by Dow Jones
10:30AM ET on Friday Nov 01, 2024 by Dow Jones
Oct 31, 2024
*DJ Agios Pharmaceuticals 3Q EPS $16.22 >AGIO, from 6:30AM ET on Thursday Oct 31, 2024 by Dow Jones
6:30AM ET on Thursday Oct 31, 2024 by Dow JonesAgios Reports Business Highlights and Third Quarter 2024 Financial Results, from 6:30AM ET on Thursday Oct 31, 2024 by Dow Jones
6:30AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Agios Pharmaceuticals Inc | 3.1B | 4.4x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Xenon Pharmaceuticals Inc | 3.0B | -14.2x | --- |
MoonLake Immunotherapeutics | 3.1B | -37.8x | --- |
Immunitybio Inc | 3.1B | -5.2x | --- |
Merus NV | 3.2B | -11.9x | --- |
Company Information
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Contact Information
- Headquarters
- 88 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-649-8600
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jacqualyn Fouse
- Chief Executive Officer, Director
- Brian Goff
- Chief Financial Officer
- Cecilia Jones
- Chief Legal Officer
- James Burns
- Chief Medical Officer, Head - Research and Development
- Sarah Gheuens
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
|---|---|
Revenue (TTM) | $32.9M |
Shares Outstanding | 57.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.73 |
EPS | $12.28 |
Book Value | $14.50 |
P/E Ratio | 4.4x |
Price/Sales (TTM) | 93.3 |
Price/Cash Flow (TTM) | 4.2x |
Operating Margin | 2,075.26% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
